Apixaban to prevent liver cirrhosis from getting worse
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether the blood thinner apixaban can help prevent early-stage cirrhosis from worsening. You may be eligible if you have compensated (stable) cirrhosis due to alcohol and have signs of portal hypertension.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cirrhosis must be caused by alcohol, with or without fatty liver disease.
- Your cirrhosis should be early-stage (Child's A) and well-compensated, meaning you haven't had serious complications recently.
- You need to have signs of high pressure in the liver's blood vessels, such as enlarged veins, a large spleen, or high liver stiffness measurement.
- You cannot have severe kidney problems (eGFR less than 30) or very low platelet counts (below 50,000).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early study tests whether the blood thinner pills rivaroxaban and apixaban can be used safely in people with liver cirrhosis that is not too severe. It may help doctors understand the safest way to prevent or treat blood clots in this group.
This Phase 2 study tests a blood-thinner called a DOAC in people with previously diagnosed mild or moderate liver cirrhosis (Child A or B). It may help doctors understand whether the medicine is safe and effective in this group.
This trial is testing whether taking a low dose of aspirin every day can lower the risk of developing liver cancer (hepatocellular carcinoma, or HCC) in people with liver cirrhosis. Liver cirrhosis is scarring of the liver, and having it increases the risk of liver cancer. If you are eligible, you would be asked to take aspirin or a placebo (a pill with no active medicine) and have regular check-ups to see if aspirin helps prevent cancer.
This Phase 2 trial tests whether giving albumin together with enoxaparin (a blood thinner) can improve outcomes for people hospitalized with decompensated cirrhosis who are at high risk. It may help your recovery after certain serious liver-related complications and reduce the chance of poor outcomes.
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
Hear when a new Liver Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.